NEOPRONTOSIL (ORAL) IN THE TREATMENT OF CHRONIC ULCERATIVE COLITIS

Publisher Website
Google Scholar
Abstract
Group A (29 patients) were given Neoprontosil (orally) only: results were excellent with 13, fair with 13, poor with 3. Group B (19 patients) received, in addition to Neoprontosil (orally), either vaccine or serum: excellent results were obtained with 8, fair results with 6, failure or poor results with 5. The clinical response to neoprontosil is not predictable on the basis of the amount of bowel involved by the disease, so long as destruction of the bowel is not too great. The prompt improvement which has occurred so frequently and uniformly after the use of neoprontosil seems to indicate that the drug is of definite benefit in this disease. The tendency of the disease to recur must be appreciated; therefore, intermittent courses of treatment were given, even when the disease has been symptomatically and objectively inactive for some months. The lack of toxic manifestations associated with the use of neoprontosil in general makes this drug especially adaptable to the treatment of chronic ulcerative colitis.

This publication has 0 references indexed in Scilit: